ATLANTA, July 22 Shire Limited(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company,today announced that it has launched VYVANSE(TM) (lisdexamfetamine dimesylate)for the treatment of adults with Attention Deficit Hyperactivity Disorder(ADHD). This launch follows the recent FDA approval of VYVANSE to treat ADHDin the adult population. VYVANSE is now available in U.S. pharmaciesnationwide in six once-daily dosage strengths. To raise awareness of ADHD inadults and recognize the launch of VYVANSE for adults, Shire has partneredwith celebrity designer Ty Pennington to shine the spotlight on living as anadult with ADHD. Pennington takes VYVANSE as part of his treatment plan tomanage his ADHD symptoms so he can focus and get work done.
Pennington returns today to his hometown of Atlanta, where he will visitthe Savannah College of Art and Design-Atlanta (SCAD-Atlanta) and announce theDaily Successes with ADHD Scholarship for an adult with ADHD who is pursuingan education or career in a creative field at SCAD-Atlanta. The $10,000scholarship, sponsored by Shire, the maker of VYVANSE, will benefit an adultwith ADHD who is enrolled in, or applying to, a graduate program at the artinstitution. The objective of the scholarship is to recognize achievements,and to motivate a student to continue to focus and achieve daily successes.
"As an adult with ADHD, I know, firsthand, the importance of understandingand treating ADHD. I believe if I'd been diagnosed and treated earlier, Iwould have struggled less as a child," said Ty Pennington, host of ABC'sExtreme Makeover: Home Edition(TM). "Today, I have a very demanding schedulewith long production days and constant travel, and I take VYVANSE to helpcontrol my ADHD symptoms so that I can focus and organize."
ADHD Can Affect Adults' Daily Lives
In adults with ADHD, symptoms can impact their professional life, sociallife, relationships and personal finances. In a new survey conducted by Shireof adults who experienced ADHD symptoms in a typical week, 88 percent of 328adults surveyed reported that they have difficulty organizing tasks andactivities, while 89 percent of 381 of these adults had difficulty finishingthings, such as projects or work at home. These adults reported that this hashad a negative impact on their daily life and activities. Additionally, amongthe 347 adults surveyed who are currently employed, 66 percent felt that theywould do a better job at work if they were more focused and organized.
"Although ADHD can affect children and adults, the core symptoms of thedisorder, inattention, hyperactivity, and impulsivity, may present differentlyin these two patient groups. For example, hyperactivity may present in adultsas inner restlessness and inattention may present as a lack of focus andorganization, poor time management, and an inability to finish tasks," saidDavid W. Goodman, M.D., director of the Adult Attention Deficit DisorderCenter of Maryland and assistant professor of psychiatry and behavioralsciences at Johns Hopkins University School of Medicine. VYVANSE is one ofseveral treatment options that may provide effective treatment control foradults with ADHD. In a clinical study, VYVANSE was shown to significantlyimprove ADHD symptoms within the first week: inattention -- such as theability to focus and organize -- and hyperactivity and impulsivity -- such asrestlessness, and interrupting."
Shire received approval in April 2008 from the FDA for VYVANSE for thetreatment of ADHD in adults aged 18 to 55 years. VYVANSE was introduced inJuly 2007 for the treatment of ADHD in children aged 6 to 12 years. VYVANSEis available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and70 mg. In its first year of availability, more than 2 million VYVANSEprescriptions have been filled.
VYVANSE works with the body's natural metabolism to